November 9, 2015
Unum Therapeutics to Present at Inaugural CAR-T Summit on the Promise of Antibody Coupled T-cell Receptor as a Universal Approach to T-Cell Therapy
CAMBRIDGE, MA, November 9, 2015 – Unum Therapeutics, a company developing a universal cellular immunotherapy to treat multiple cancers, announced that Chief Scientific Officer Seth Ettenberg, Ph.D., and his team are set to speak at the first CAR-T Summit, to be held this week in Cambridge, Massachusetts.
Dr. Ettenberg is part of a distinguished lineup of speakers that will address various issues associated with the discovery, development and manufacturing of economically viable CAR-T cell therapies. His presentation, “ACTR, a Universal Approach to CART Therapy,” will take place on Thursday, November 12, at 3:40 p.m. EST.
The half-hour presentation will serve as an introduction to the universal receptor, which Unum has been studying as part of its clinical drug discovery platform. To date, Dr. Ettenberg and his research team have demonstrated in vivo a more universal approach to T-cell therapy by engineering T-cells to express an antibody coupled T-cell receptor, or ACTR. This allows for the ability to produce one cell product for many different cancers, and can also be combined with many tumor-targeting antibodies, creating a universal T-cell product.
“Armed with impressive clinical validation, immuno-oncology cell therapy holds great promise,” said Dr. Ettenberg. “I look forward to joining in the conversation – with a lineup of prominent figures in this space – to discuss how continued innovation will help bring new treatments to the people facing many difficult-to-treat cancers.”
Dr. Ettenberg will also participate in a panel to discuss the following topic: “Cutting-Edge Efficacy Data from Improved Chimeric Antigen Receptors: What Lessons Have Been Learned So Far to Future Proof Clinically Successful CAR-T Cell Therapies.” This panel will convene at 4:40 p.m. EST that same day.
Finally, Heather Huet, Ph.D., Director of Drug Discovery at Unum, will present an abstract that tackles many of the topics of Dr. Ettenberg’s talk in greater detail. Through its proprietary T-cell technology, Unum believes it can transform cancer treatment through the development and commercialization of novel antibody-couple cellular immunotherapies. Recruitment is already underway for a Phase 1 clinical trial in Singapore evaluating ATTCK20, the combination of ACTR T-cells with Rituxan, one of the earliest monoclonal antibodies approved by the U.S. Food and Drug Administration.
About Unum Therapeutics
Unum Therapeutics uses proprietary T-cell engineering technology in combination with tumor-targeting antibodies to activate the body’s own immune system to fight cancer. Unum’s lead program, based on its Antibody-Coupled T-cell Receptor (ACTR) technology, recently entered Phase 1 clinical testing to assess safety and efficacy. The company is headquartered in Cambridge, MA. For more information, visit www.unumrx.com.